Comparing two blood sugar targets in children and teens with type 1 diabetes
Compares two blood sugar targets in young people with type 1 diabetes.
Plain-language title generated from the registry record
Registry title: Time in rANge vs. Time in nOrmal Glycemia for Better Glycemic Control
Key facts
- Where
- Petah Tikva, IsraelSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 5 and 18 years old?
Source: NCT07376850, who can take part
Where in Israel
- Schneider Children's Medical Center of IsraelPetah Tikva, IsraelNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Motol
- Trial code
- NCT07376850
- Record updated
- 29 January 2026
- Original description
The TANGO study is a 12-month study involving 120 children and adolescents with Type 1 Diabetes (T1D) across the Czech Republic, Israel, and Poland who use automated insulin delivery (AID) systems.Read full original descriptionShow less
Time in rANge vs. Time in nOrmal Glycemia for Better Glycemic Control
The TANGO study is a 12-month study involving 120 children and adolescents with Type 1 Diabetes (T1D) across the Czech Republic, Israel, and Poland who use automated insulin delivery (AID) systems.
Currently, the global standard for diabetes management is "Time in Range" (TIR), which aims to keep blood sugar levels between 70-180 mg/dL. However, newer technologies like AID systems may now allow for a tighter, more physiological goal called "Time in Normal Glycemia" (TING), which targets a range of 70-140 mg/dL.
This study will randomly assign participants to follow either the standard TIR target or the tighter TING target to see if the narrower range improves overall blood sugar control and HbA1c without increasing the risk of hypoglycemia, family stress, or daily treatment burden.
By comparing these two approaches, researchers hope to determine if clinical guidelines should be updated to reflect a more precise glucose target for children and adolescents worldwide
Inclusion: Diagnosis of T1D per ADA criteria; Age 5.0-17.99 at the start of study; CGM use >70% of the time during the month prior to enrollment; Maximum HbA1c of 86mmol/mol (10% in DCCT).
Exclusion: No concurrent illnesses impacting glycemia; Any significant diseases / conditions including psychiatric disorders and substance abuse that in the opinion of the investigator is likely to affect the subject's ability to complete the study or compromise participant's safety; No treatments impacting glycemia; Severe hypoglycemia documented in the 60 day period leading up to patient recruitment; Current participation in any other interventional study; Female subject who is pregnant or lactating or planning to become pregnant within the planned study duration.